$1.12
3.57%
Downside
Day's Volatility :7.69%
Upside
4.27%
63.16%
Downside
52 Weeks Volatility :78.6%
Upside
41.91%
Period | Nektar Therapeutics | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -11.11% | 5.1% | 0.0% |
6 Months | 17.2% | 4.9% | 0.0% |
1 Year | 88.55% | 16.6% | 0.0% |
3 Years | -93.01% | 13.2% | -22.3% |
Market Capitalization | 208.0M |
Book Value | $0.43 |
Earnings Per Share (EPS) | -0.89 |
PEG Ratio | 3.22 |
Wall Street Target Price | 1.3 |
Profit Margin | -190.09% |
Operating Margin TTM | -155.33% |
Return On Assets TTM | -20.16% |
Return On Equity TTM | -128.02% |
Revenue TTM | 93.2M |
Revenue Per Share TTM | 0.48 |
Quarterly Revenue Growth YOY | 14.6% |
Gross Profit TTM | 70.4M |
EBITDA | -128.7M |
Diluted Eps TTM | -0.89 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.83 |
EPS Estimate Next Year | -0.68 |
EPS Estimate Current Quarter | -0.2 |
EPS Estimate Next Quarter | -0.21 |
What analysts predicted
Upside of 16.07%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 1.2B | ↑ 287.81% |
Net Income | 681.3M | ↓ 804.62% |
Net Profit Margin | 57.09% | ↑ 88.51% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 114.6M | ↓ 90.4% |
Net Income | -440.7M | ↓ 164.68% |
Net Profit Margin | -384.47% | ↓ 441.56% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 152.9M | ↑ 33.41% |
Net Income | -444.4M | ↑ 0.86% |
Net Profit Margin | -290.65% | ↑ 93.82% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 101.9M | ↓ 33.36% |
Net Income | -523.8M | ↑ 17.86% |
Net Profit Margin | -514.03% | ↓ 223.38% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 92.1M | ↓ 9.67% |
Net Income | -368.2M | ↓ 29.71% |
Net Profit Margin | -399.98% | ↑ 114.05% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 90.1M | ↓ 2.1% |
Net Income | -276.1M | ↓ 25.03% |
Net Profit Margin | -306.31% | ↑ 93.67% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 21.6M | ↓ 1.95% |
Net Income | -137.0M | ↑ 129.56% |
Net Profit Margin | -634.52% | ↓ 363.49% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 20.5M | ↓ 5.07% |
Net Income | -51.1M | ↓ 62.69% |
Net Profit Margin | -249.39% | ↑ 385.13% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 24.1M | ↑ 17.78% |
Net Income | -45.8M | ↓ 10.34% |
Net Profit Margin | -189.85% | ↑ 59.54% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 23.9M | ↓ 1.07% |
Net Income | -42.1M | ↓ 8.2% |
Net Profit Margin | -176.17% | ↑ 13.68% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 21.6M | ↓ 9.4% |
Net Income | -36.8M | ↓ 12.54% |
Net Profit Margin | -170.07% | ↑ 6.1% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 23.5M | ↑ 8.55% |
Net Income | -52.4M | ↑ 42.28% |
Net Profit Margin | -222.93% | ↓ 52.86% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 2.2B | ↑ 322.54% |
Total Liabilities | 432.6M | ↑ 2.75% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 2.0B | ↓ 8.04% |
Total Liabilities | 572.0M | ↑ 32.22% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.5B | ↓ 22.18% |
Total Liabilities | 461.5M | ↓ 19.32% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.1B | ↓ 27.4% |
Total Liabilities | 437.7M | ↓ 5.16% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 710.6M | ↓ 36.39% |
Total Liabilities | 344.0M | ↓ 21.41% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 398.0M | ↓ 43.99% |
Total Liabilities | 267.0M | ↓ 22.36% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 561.7M | ↓ 20.95% |
Total Liabilities | 320.9M | ↓ 6.71% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 494.3M | ↓ 12.01% |
Total Liabilities | 297.3M | ↓ 7.34% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 442.2M | ↓ 10.53% |
Total Liabilities | 282.9M | ↓ 4.86% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 398.0M | ↓ 10.0% |
Total Liabilities | 267.0M | ↓ 5.6% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 396.0M | ↓ 0.51% |
Total Liabilities | 269.3M | ↑ 0.85% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 343.3M | ↓ 13.3% |
Total Liabilities | 263.6M | ↓ 2.1% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 718.2M | ↓ 993.15% |
Investing Cash Flow | -1.4B | ↑ 4689.95% |
Financing Cash Flow | 852.0M | ↑ 1466.37% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -328.7M | ↓ 145.76% |
Investing Cash Flow | 206.9M | ↓ 114.99% |
Financing Cash Flow | 23.4M | ↓ 97.26% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -313.3M | ↓ 4.68% |
Investing Cash Flow | 496.2M | ↑ 139.85% |
Financing Cash Flow | -80.4M | ↓ 444.05% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -412.7M | ↑ 31.72% |
Investing Cash Flow | 202.8M | ↓ 59.14% |
Financing Cash Flow | 36.2M | ↓ 145.1% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -304.0M | ↓ 26.33% |
Investing Cash Flow | 365.8M | ↑ 80.41% |
Financing Cash Flow | 1.5M | ↓ 95.84% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -51.9M | ↓ 10.03% |
Investing Cash Flow | 40.6M | ↑ 1.46% |
Financing Cash Flow | 18.0K | ↓ 82.52% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -51.5M | ↓ 0.76% |
Investing Cash Flow | 25.2M | ↓ 38.0% |
Financing Cash Flow | 18.0K | ↑ 0.0% |
Sell
Neutral
Buy
Nektar Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Nektar Therapeutics | -5.08% | 17.2% | 88.55% | -93.01% | -93.73% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Nektar Therapeutics | NA | NA | 3.22 | -0.83 | -1.28 | -0.2 | NA | 0.43 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Nektar Therapeutics | Hold | $208.0M | -93.73% | NA | -190.09% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Nektar Therapeutics
Revenue is up for the last 2 quarters, 21.63M → 23.48M (in $), with an average increase of 7.9% per quarter
Netprofit is down for the last 2 quarters, -36.80M → -52.36M (in $), with an average decrease of 42.3% per quarter
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 162.2%
Deep Track Capital, LP
BlackRock Inc
Vanguard Group Inc
Samlyn Capital, LLC
Acadian Asset Management LLC
Eventide Asset Management, LLC
nektar therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. nektar also partners with the top biopharmaceutical companies to bring new products to market. to date, nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.
Organization | Nektar Therapeutics |
Employees | 137 |
CEO | Mr. Howard W. Robin |
Industry | Health Technology |
A Spac I Acquisition Corp
$1.12
-0.88%
Keyarch Acquisition Corp
$1.12
-0.88%
Connexa Sports Technologies Inc
$1.12
-0.88%
Us Value Etf
$1.12
-0.88%
First Wave Biopharma Inc
$1.12
-0.88%
Global X Msci Next Emerging
$1.12
-0.88%
Fat Projects Acquisition Corp
$1.12
-0.88%
Capital Link Global Fintech
$1.12
-0.88%
Applied Uv Inc
$1.12
-0.88%